Dr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).
This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).
The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.
Approximate Time to Complete: 1 hour
Course Available Beginning: Dec. 19, 2018 - Dec. 19, 2019
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the latest clinical trial data on the care of patients with metastatic renal cell carcinoma (mRCC)
- Have greater competence related to incorporating team-based strategies for monitoring and managing treatment-related adverse effects
- Have greater competence related to choosing the most appropriate regimen for patients with mRCC across the continuum of care
- Have greater competence related to coordinating care among an interprofessional team to ensure timely delivery of care